Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0SJ8Q
|
||||
| Former ID |
DNC009286
|
||||
| Drug Name |
ERITORAN
|
||||
| Drug Type |
Small molecular drug
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C66H126N2O19P2
|
||||
| InChI |
InChI=1S/C66H126N2O19P2/c1-7-11-15-19-22-25-26-27-28-29-30-32-34-38-42-46-57(70)67-60-64(82-49-47-54(80-6)45-41-36-18-14-10-4)62(86-88(73,74)75)56(51-79-5)85-65(60)83-52-55-61(72)63(81-48-43-39-35-24-21-17-13-9-3)59(66(84-55)87-89(76,77)78)68-58(71)50-53(69)44-40-37-33-31-23-20-16-12-8-2/h25-26,54-56,59-66,72H,7-24,27-52H2,1-6H3,(H,67,70)(H,68,71)(H2,73,74,75)(H2,76,77,78)/b26-25-/t54-,55-,56-,59-,60-,61-,62-,63-,64-,65-,66-/m1/s1
|
||||
| InChIKey |
BPSMYQFMCXXNPC-MFCPCZTFSA-N
|
||||
| CAS Number |
CAS 185955-34-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Toll-like receptor 4 | Target Info | Inhibitor | [529731] | |
| KEGG Pathway | NF-kappa B signaling pathway | ||||
| HIF-1 signaling pathway | |||||
| Phagosome | |||||
| PI3K-Akt signaling pathway | |||||
| Toll-like receptor signaling pathway | |||||
| Pathogenic Escherichia coli infection | |||||
| Salmonella infection | |||||
| Pertussis | |||||
| Legionellosis | |||||
| Leishmaniasis | |||||
| Chagas disease (American trypanosomiasis) | |||||
| Malaria | |||||
| Toxoplasmosis | |||||
| Amoebiasis | |||||
| Tuberculosis | |||||
| Hepatitis B | |||||
| Measles | |||||
| Influenza A | |||||
| Proteoglycans in cancer | |||||
| Inflammatory bowel disease (IBD) | |||||
| Rheumatoid arthritis | |||||
| PANTHER Pathway | Toll receptor signaling pathway | ||||
| Pathway Interaction Database | Endogenous TLR signaling | ||||
| Reactome | Ligand-dependent caspase activation | ||||
| Toll Like Receptor 4 (TLR4) Cascade | |||||
| MyD88:Mal cascade initiated on plasma membrane | |||||
| MyD88-independent TLR3/TLR4 cascade | |||||
| TRIF-mediated programmed cell death | |||||
| MyD88 deficiency (TLR2/4) | |||||
| IRAK4 deficiency (TLR2/4) | |||||
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | |||||
| IKK complex recruitment mediated by RIP1 | |||||
| TRAF6 mediated induction of TAK1 complex | |||||
| WikiPathways | Toll-like receptor signaling pathway | ||||
| Toll-Like Receptors Cascades | |||||
| MyD88:Mal cascade initiated on plasma membrane | |||||
| MyD88-independent cascade | |||||
| Primary Focal Segmental Glomerulosclerosis FSGS | |||||
| Spinal Cord Injury | |||||
| Corticotropin-releasing hormone | |||||
| Pathogenic Escherichia coli infection | |||||
| Regulation of toll-like receptor signaling pathway | |||||
| References | |||||
| Ref 468097 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4919). | ||||
| Ref 521840 | ClinicalTrials.gov (NCT00334828) ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.